News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Digilab BioVisioN GmbH Peptidomics Receives United States Patent for Alzheimer's Disease Biomarkers


7/11/2007 12:09:58 PM

HANNOVER, Germany--(BUSINESS WIRE)--Digilab Peptidomics®, formerly BioVisioN, was granted a patent by the US Patent Office for a new panel of biomarkers for the diagnosis of chronic dementia or a predisposition to such diseases. Using proprietary Peptidomics®-Technologies, scientists from Digilab Inc have discovered a group of Osteonpontin marker peptides that correlates to Alzheimer’s Disease, Vascular Dementia, and Parkinson’s Disease. A method for early and reliable detection based on Digilab’s Peptidomics® biomarkers will enable the development of novel therapies for this segment of CNS diseases with debilitating patient care medical consequences.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES